Marcus Capital LLC lessened its position in shares of Global Blood Therapeutics, Inc. (NASDAQ:GBT) by 52.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 31,200 shares of the company’s stock after selling 34,150 shares during the period. Marcus Capital LLC owned 0.07% of Global Blood Therapeutics worth $969,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. BNP Paribas Arbitrage SA lifted its position in shares of Global Blood Therapeutics by 694.9% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,547 shares of the company’s stock valued at $124,000 after buying an additional 3,975 shares during the last quarter. Legal & General Group Plc lifted its position in shares of Global Blood Therapeutics by 10.1% during the 1st quarter. Legal & General Group Plc now owns 4,816 shares of the company’s stock valued at $178,000 after buying an additional 440 shares during the last quarter. Bank of America Corp DE lifted its position in shares of Global Blood Therapeutics by 103.6% during the 1st quarter. Bank of America Corp DE now owns 7,141 shares of the company’s stock valued at $263,000 after buying an additional 3,633 shares during the last quarter. DekaBank Deutsche Girozentrale purchased a new position in shares of Global Blood Therapeutics during the 2nd quarter valued at $211,000. Finally, Raymond James Financial Services Advisors Inc. purchased a new position in shares of Global Blood Therapeutics during the 3rd quarter valued at $230,000. 86.76% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION NOTICE: “Marcus Capital LLC Sells 34,150 Shares of Global Blood Therapeutics, Inc. (GBT)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.thecerbatgem.com/2017/11/15/marcus-capital-llc-sells-34150-shares-of-global-blood-therapeutics-inc-gbt.html.

In other Global Blood Therapeutics news, insider Jung Choi sold 3,000 shares of the company’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $30.00, for a total value of $90,000.00. Following the transaction, the insider now directly owns 140,055 shares in the company, valued at approximately $4,201,650. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Peter Radovich sold 12,500 shares of the company’s stock in a transaction dated Monday, October 30th. The stock was sold at an average price of $35.00, for a total value of $437,500.00. Following the completion of the transaction, the vice president now owns 2,684 shares in the company, valued at $93,940. The disclosure for this sale can be found here. Insiders sold a total of 91,500 shares of company stock worth $3,093,350 over the last 90 days. Corporate insiders own 5.30% of the company’s stock.

Global Blood Therapeutics, Inc. (NASDAQ:GBT) traded up $1.40 during trading hours on Wednesday, hitting $38.85. The company had a trading volume of 489,394 shares, compared to its average volume of 1,005,755. Global Blood Therapeutics, Inc. has a 12 month low of $13.35 and a 12 month high of $43.95.

Global Blood Therapeutics (NASDAQ:GBT) last released its quarterly earnings data on Thursday, November 2nd. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.62) by ($0.04). During the same quarter in the prior year, the company posted ($0.58) earnings per share. research analysts anticipate that Global Blood Therapeutics, Inc. will post -2.52 earnings per share for the current year.

A number of brokerages have recently commented on GBT. Oppenheimer Holdings, Inc. set a $53.00 price target on Global Blood Therapeutics and gave the company a “buy” rating in a research report on Monday, October 30th. BidaskClub cut Global Blood Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Global Blood Therapeutics in a research report on Monday, October 23rd. Zacks Investment Research raised Global Blood Therapeutics from a “hold” rating to a “buy” rating and set a $36.00 price target on the stock in a research report on Tuesday, October 10th. Finally, Needham & Company LLC began coverage on Global Blood Therapeutics in a research report on Wednesday, September 20th. They set a “buy” rating and a $51.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $55.00.

Global Blood Therapeutics Profile

Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).

Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Receive News & Stock Ratings for Global Blood Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics Inc. and related stocks with our FREE daily email newsletter.